Biogen sees Leqembi Intravenous Infusion for AD launched in Japan on Dec 20

Eisai Co., (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody “Leqembi Intravenous Infusion” will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance, or NHI, Drug Price List. “The launch in Japan marks the second country to have LEQEMBI on the market, following the traditional approval in the United States. In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder,” the companies stated.